These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 33525721)

  • 41. Impact of Nanostructured Lipid Carriers as an Artificial Tear Film in a Rabbit Evaporative Dry Eye Model.
    Niamprem P; Teapavarapruk P; Srinivas SP; Tiyaboonchai W
    Cornea; 2019 Apr; 38(4):485-491. PubMed ID: 30681516
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Poly(lactic-co-glycolic acid) Nanoparticles Encapsulating the Prenylated Flavonoid, Xanthohumol, Protect Corneal Epithelial Cells from Dry Eye Disease-Associated Oxidative Stress.
    Ghosh AK; Thapa R; Hariani HN; Volyanyuk M; Ogle SD; Orloff KA; Ankireddy S; Lai K; Žiniauskaitė A; Stubbs EB; Kalesnykas G; Hakkarainen JJ; Langert KA; Kaja S
    Pharmaceutics; 2021 Aug; 13(9):. PubMed ID: 34575438
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical utility of 3% diquafosol ophthalmic solution in the treatment of dry eyes.
    Koh S
    Clin Ophthalmol; 2015; 9():865-72. PubMed ID: 26028958
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of a New Ocular Surface Modulator in Restoring Epithelial Changes in an In Vitro Model of Dry Eye Syndrome.
    Barabino S; De Servi B; Aragona S; Manenti D; Meloni M
    Curr Eye Res; 2017 Mar; 42(3):358-363. PubMed ID: 27163340
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Assessment of Langerhans Cells in the Central Cornea as Tool for Monitoring Inflammatory Changes in Patients with Keratoconjunctivitis sicca under Topical Therapy with Cyclosporine A 0.05% Eye Drops].
    Schneider E; Paulsen F; Jacobi C
    Klin Monbl Augenheilkd; 2020 May; 237(5):669-674. PubMed ID: 32434251
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dry Eye Disease: Early Recognition with Guidance on Management and Treatment for Primary Care Family Physicians.
    Verjee MA; Brissette AR; Starr CE
    Ophthalmol Ther; 2020 Dec; 9(4):877-888. PubMed ID: 33090327
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In pursuit of objective dry eye screening clinical techniques.
    Kanellopoulos AJ; Asimellis G
    Eye Vis (Lond); 2016; 3():1. PubMed ID: 26783543
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Tear film analysis and evaluation of optical quality: A review of the literature (French translation of the article)].
    Herbaut A; Liang H; Denoyer A; Baudouin C; Labbé A
    J Fr Ophtalmol; 2019 Mar; 42(3):226-243. PubMed ID: 30879832
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tear Osmolarity and Correlation With Ocular Surface Parameters in Patients With Dry Eye.
    Mathews PM; Karakus S; Agrawal D; Hindman HB; Ramulu PY; Akpek EK
    Cornea; 2017 Nov; 36(11):1352-1357. PubMed ID: 28872518
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A study of refractory cases of persistent epithelial defects associated with dry eye syndrome and recurrent corneal erosions successfully treated with cyclosporine A 0.05% eye drops.
    Napoli PE; Braghiroli M; Iovino C; Demarinis G; Fossarello M
    Drug Des Devel Ther; 2019; 13():2001-2008. PubMed ID: 31354245
    [No Abstract]   [Full Text] [Related]  

  • 51. Ocular Delivery of Polyphenols: Meeting the Unmet Needs.
    Krstić L; González-García MJ; Diebold Y
    Molecules; 2021 Jan; 26(2):. PubMed ID: 33445725
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy in patients with dry eye after treatment with a new lubricant eye drop formulation.
    Davitt WF; Bloomenstein M; Christensen M; Martin AE
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):347-53. PubMed ID: 20653478
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness and relevant factors of 2% rebamipide ophthalmic suspension treatment in dry eye.
    Ueda K; Matsumiya W; Otsuka K; Maeda Y; Nagai T; Nakamura M
    BMC Ophthalmol; 2015 Jun; 15():58. PubMed ID: 26048396
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Tears osmolarity in dry eye].
    Aguilar AJ
    Arq Bras Oftalmol; 2008; 71(6 Suppl):69-71. PubMed ID: 19274415
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of Lipid Peroxidation Markers in the Tear Film and Ocular Surface of Patients with Non-Sjogren Syndrome: Potential Biomarkers for Dry Eye Disease.
    Choi W; Lian C; Ying L; Kim GE; You IC; Park SH; Yoon KC
    Curr Eye Res; 2016 Sep; 41(9):1143-9. PubMed ID: 26731289
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Current methods of tear film stability assessment].
    Safonova TN; Sikach EI; Ozheredov IA
    Vestn Oftalmol; 2019; 135(5):92-98. PubMed ID: 31714519
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [TOPICAL ANTI-INFLAMMATORY AGENTS FOR DRY EYE DISEASE].
    Erdinest N; Solomon A
    Harefuah; 2019 Feb; 158(2):130-135. PubMed ID: 30779493
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Towards a new in vitro model of dry eye: the Ex Vivo Eye Irritation Test.
    Spöler F; Frentz M; Schrage NF
    Dev Ophthalmol; 2010; 45():93-107. PubMed ID: 20502030
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Trehalose augments autophagy to mitigate stress induced inflammation in human corneal cells.
    Panigrahi T; Shivakumar S; Shetty R; D'souza S; Nelson EJR; Sethu S; Jeyabalan N; Ghosh A
    Ocul Surf; 2019 Oct; 17(4):699-713. PubMed ID: 31412290
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Manganese(III) tetrakis(1-methyl-4-pyridyl) porphyrin, a superoxide dismutase mimetic, reduces disease severity in in vitro and in vivo models for dry-eye disease.
    Žiniauskaitė A; Ragauskas S; Ghosh AK; Thapa R; Roessler AE; Koulen P; Kalesnykas G; Hakkarainen JJ; Kaja S
    Ocul Surf; 2019 Apr; 17(2):257-264. PubMed ID: 30807830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.